8-K: Amwell Announces First Quarter 2025 Results, Highlights Progress in Strategic Initiatives

Amwell reports Q1 2025 financial results, showing revenue of $66.8 million and progress towards cash flow breakeven in 2026.

Summary

• Amwell announced its financial results for the first quarter of 2025.
• Total revenue for Q1 2025 was $66.8 million.
• Subscription revenue reached $32.2 million.
• Amwell Medical Group (AMG) visit revenue was $26.6 million.
• The company reported a gross margin of 53%.
• Net loss was ($18.4) million, an improvement from ($44.6) million in Q4 2024.
• Adjusted EBITDA was ($12.2) million, compared to ($22.8) million in Q4 2024.
• Total visits were 1.3 million.
• The company reiterated its 2025 revenue guidance of $250 to $260 million.
• AMG visits are expected to be between 1.3 and 1.35 million for 2025.
• Adjusted EBITDA for 2025 is projected to be between ($55) million and ($45) million.
• Q2 2025 revenue is expected to be in the range of $62 to $67 million.
• Q2 2025 adjusted EBITDA is projected to be in the range of ($12) to ($10) million.
• Amwell aims to achieve positive cash flow from operations in 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company is still reporting losses, there's clear progress in reducing those losses and a reiterated commitment to achieving positive cash flow in 2026. The reaffirmed guidance and strategic initiatives contribute to the positive outlook.

Positives

• Amwell's Q1 2025 results show improvement in net loss and adjusted EBITDA compared to the previous quarter.
• The company is making progress in its strategic initiatives, including the launch of its solution across the Military Health System.
• Amwell is targeting meaningful margin expansion this year.
• The company reiterated its objective to achieve positive cash flow from operations in 2026.

Negatives

• Amwell reported a net loss of ($18.4) million for Q1 2025, although it is an improvement from the previous quarter.
• Adjusted EBITDA is still negative at ($12.2) million for Q1 2025.
• The company's guidance is provided on a non-GAAP basis, and a reconciliation to GAAP net income is not provided due to forecasting difficulties.

Risks

• The company's ability to successfully transition clients to Converge without significant attrition is a risk.
• Renewing and upselling the client base is crucial for future growth.
• The continuation of the DHA relationship beyond July 2025 with comparable financial terms is uncertain.
• Weak growth and increased volatility in the telehealth market could impact performance.
• Adapting to rapid technological changes is essential for maintaining competitiveness.
• Increased competition from existing and potential new participants in the healthcare industry poses a threat.
• Changes in healthcare laws, regulations, or trends could affect operations.
• Complying with federal and state privacy regulations is critical.
• A cybersecurity breach could result in significant liability.
• The company's ability to commence and complete strategic transformation initiatives is uncertain.

Future Outlook

Amwell expects revenue in the range of $250 to $260 million and adjusted EBITDA between ($55) million and ($45) million for 2025, and aims to achieve positive cash flow from operations in 2026.

Management Comments

• Ido Schoenberg, MD, chairman and CEO, stated that Amwell had a strong Q1 across all strategic initiatives.
• Ido Schoenberg mentioned the progress in the staged launch of their full solution across the Military Health System with Leidos partners.
• Ido Schoenberg noted significant progress in revenue quality and cost alignment measures.
• Ido Schoenberg stated that they are targeting meaningful margin expansion this year.
• Ido Schoenberg said that with another strong quarter of EBITDA improvement, they are taking a step closer to their goal of achieving cash flow breakeven from operations in 2026.

Industry Context

Amwell operates in the telehealth industry, which is experiencing growth and increased competition. The company's focus on a comprehensive SaaS-based technology-enabled healthcare platform positions it to capitalize on the increasing demand for virtual care solutions. The partnership with Leidos to serve the Military Health System is a significant opportunity. The company faces competition from other telehealth providers and traditional healthcare organizations.

Comparison to Industry Standards

• Teladoc Health, a major competitor in the telehealth space, reported Q1 2024 revenue of $629.2 million, showcasing a significantly larger scale of operations compared to Amwell's $66.8 million.
• While Teladoc's net loss was $81.8 million, it's important to consider the difference in revenue scale when comparing profitability metrics.
• Another competitor, GlobalMed, focuses on enterprise telehealth solutions, similar to Amwell's SaaS-based platform approach.
• Companies like Zoom and Microsoft are also expanding into telehealth with communication and collaboration tools, increasing competition.
• Industry benchmarks suggest that successful telehealth companies are focusing on integrated care models, data analytics, and personalized patient experiences, areas where Amwell is also investing.

Related Party Transactions

• Accounts receivable from related parties were $450 thousand as of March 31, 2025.
• Revenue from related parties was $432 thousand for the three months ended March 31, 2025.

Stakeholder Impact

• Shareholders may be encouraged by the improved financial performance and the company's commitment to achieving positive cash flow.
• Employees may be affected by strategic transformation costs, including potential severance.
• Customers (payers and health systems) can expect continued investment in the Amwell platform and its capabilities.
• Suppliers and creditors will be impacted by the company's overall financial health and ability to meet its obligations.

Next Steps

• The company will continue to focus on transitioning clients to Converge.
• Amwell will work on renewing and upselling its client base.
• The company will monitor the Defense Health Agency's decision to deploy their solution across the entire enterprise.
• Amwell will continue to adapt to rapid technological changes.
• The company will focus on strategic transformation initiatives.

Key Dates

Keywords

Amwell, telehealth, SaaS, healthcare, financial results, revenue, EBITDA, AMG, Military Health System, Converge